---
company: CNO Financial Group, Inc.
ticker: CNO
form: 8-K
filed: 2026-07-30
accession: 0001224608-26-000061
source: https://www.sec.gov/Archives/edgar/data/1224608/000122460826000061/
---

# CNO Financial Group (CNO) earnings release, July 30, 2026

CNO Financial Group, Inc. (CNO) · Form 8-K, Item 2.02 · Filed 2026-07-30 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1224608/000122460826000061/)

News

CNO Financial Group Reports Second Quarter 2026 Results

Carmel, Ind., July 30, 2026 -

CNO Financial Group, Inc. (NYSE: CNO) today reported its second quarter 2026 financial results:

• Strong execution and momentum continues; Raising 2026 operating earnings per share (EPS) guidance by 8% at the midpoint from our prior guidance.

• Net income was $126 million, or $1.33 per diluted share, and net operating income

(1) was $120 million, or $1.26 per diluted share.

• Operating EPS grew 45% in the quarter and 39% year-to-date.

• Return on equity (ROE) of 10.9%; Operating ROE

(5) of 13.1%, excluding significant items

(5).

• Book value per share of $27.96 and book value per diluted share, excluding accumulated other comprehensive loss,

(2) of $39.92, up 5%.

• Total new annualized premiums (NAP)

(4) up 7%, extending our track record of insurance sales growth to 16 consecutive quarters.

• Achieved quarterly records in Worksite Division NAP, Annuity collected premiums and client assets in brokerage and advisory.

• Consumer and Worksite delivered their 14 th and 16 th consecutive quarters of producing agent count growth, respectively.

“CNO delivered a very strong first half, with second quarter operating earnings per share up 45% and our 16th consecutive quarter of sales growth,” said Gary C. Bhojwani, chief executive officer.

“We are raising full-year guidance on operating earnings per share to reflect strong underlying fundamentals, continued profitability improvement and the consistent, repeatable results we continue to generate across the business.”

FINANCIAL SUMMARY

Quarter End

(Amounts in millions, except per share data)

(Unaudited)

Net income in 2Q26 and 2Q25 was higher than operating income primarily driven by non-economic accounting impacts from market volatility, partially offset by investment losses that are treated as non-operating income.

Net operating income, a non-GAAP

(a) financial measure, excludes these non-economic accounting impacts as well as other non-operating items. Net operating income is used consistently by CNO’s management to evaluate the operating performance of the Company and is a measure commonly used in the life insurance industry. It differs from net income primarily because it excludes the non-operating items as defined in note (1). Management believes an analysis of net operating income is important in understanding the profitability and operating trends of the Company’s business. Net income is the most directly comparable GAAP measure.

In 2Q26 and 2Q25, net income and net operating income

(1) were unaffected by significant items. Significant items are detailed in note (6).

____________________

(a) GAAP is defined as accounting principles generally accepted in the United States of America.

(b) Income from insurance products is the sum of the insurance product margins of the annuity, health and life product lines, less expenses allocated to the insurance product lines. It excludes the income from our fee income business, investment income not allocated to product lines, net expenses not allocated to product lines (primarily holding company expenses) and income taxes. Insurance product margin is management’s measure of the profitability of its annuity, health and life product lines’ performance and consists of insurance policy income plus allocated investment income less insurance policy benefits, interest credited, commissions, advertising expense and amortization of acquisition costs.

(c) Investment income not allocated to product lines represents net investment income less: (i) equity returns credited to policyholder account balances; (ii) the investment income allocated to our product lines; (iii) interest expense on notes payable, investment borrowings and financing arrangements; (iv) expenses related to the funding agreement-backed notes ("FABN") program; and (v) certain expenses related to benefit plans that are offset by special-purpose investment income; plus (vi) the impact of annual option forfeitures related to fixed indexed annuity surrenders. Investment income not allocated to product lines includes investment income on investments in excess of amounts allocated to product lines, investments held by our holding companies, the spread we earn from our Federal Home Loan Bank ("FHLB") investment borrowing and FABN programs and variable components of investment income (including call and prepayment income, adjustments to returns on structured securities due to cash flow changes, income (loss) from company-owned life insurance ("COLI") and alternative investment income not allocated to product lines), net of interest expense on corporate debt and financing arrangements. The spread earned from our FHLB investment borrowing and FABN programs includes the investment income on the matched assets less: (i) interest on investment borrowings related to the FHLB investment borrowing program; (ii) interest credited on funding agreements; and (iii) amortization of deferred acquisition costs related to the FABN program.²

FINANCIAL SUMMARY (continued)

Management vs. GAAP Measures

(Dollars in millions, except per share data)

(Unaudited)... (truncated)ccordingly, will not provide a return to shareholders until after it is realized as a reduction to taxes that would otherwise be paid. Management believes that excluding this value from the equity component of this measure enhances the understanding of the effect these non-discounted assets have on operating returns.

___________________________________________________________________________________________________³

Non-Operating Items

Net investment losses in 2Q26 were $13.6 million, including the unfavorable change in the allowance for credit losses of $3.4 million. Net investment losses in 2Q25 were $21.8 million, including the unfavorable change in the allowance for credit losses of $1.0 million.

During 2Q26 and 2Q25, we recognized a decrease in earnings of $1.1 million and an increase of $3.4 million, respectively, due to the net change in market value of investments.

During 2Q26 and 2Q25, we recognized an increase in earnings of $34.6 million and $25.2 million, respectively, resulting from changes in the estimated fair value of embedded derivative liabilities and market risk benefits related to our fixed indexed annuities. Such amounts include the impacts of changes in market interest rates and equity impacts used to determine the estimated fair values of the embedded derivatives and market risk benefits, and changes in equity volatility.

During 2Q26 and 2Q25, we incurred $9.7 million and $3.2 million, respectively, of expense related to TechMod, our technology modernization initiative. This three-year project began in the second quarter of 2025 to modernize certain elements of our technology.

We recognized a $1.1 million non-operating loss related to our previously announced exit from the fee services side of the Worksite business during 2Q26. Beginning in 4Q25, operating losses, including costs to exit this business, are reported in non-operating income. These operating losses were previously reported in operating income as a component of fee income.

Statutory (based on non-GAAP measures) and GAAP Capital Information

The consolidated statutory risk-based capital ratio of our U.S. based insurance subsidiaries was estimated at 377% at June 30, 2026, reflecting estimated 2Q26 statutory operating gain of $35.4 million. There were $20.0 million of company dividends paid to the holding company during 2Q26.

During 2Q26, we repurchased $60.0 million of common stock under our securities repurchase program. We repurchased 1.3 million common shares at an average cost of $46.57 per share. As of June 30, 2026, we had 92.7 million shares outstanding and had authority to repurchase up to an additional $300.4 million of our common stock. During 2Q26, dividends paid on common stock totaled $16.8 million.

Unrestricted cash and investments held by our holding company were $233.2 million at June 30, 2026 compared to $351.4 million at December 31, 2025.

Book value per common share was $27.96 at June 30, 2026 compared to $27.92 at December 31, 2025. Book value per diluted share, excluding accumulated other comprehensive income (loss)

(2), was $39.92 at June 30, 2026 compared to $38.81 at December 31, 2025.

The debt-to-capital ratio was 34.0% and 33.6% at June 30, 2026 and December 31, 2025, respectively. Our debt-to-total capital ratio, excluding accumulated other comprehensive income (loss)

(3), was 26.1% and 26.2% at June 30, 2026 and December 31, 2025, respectively.

Return on equity for the trailing four quarters ended June 30, 2026 and 2025 was 10.9% and 11.9%, respectively. Operating return on equity, excluding significant items

(5), for the trailing four quarters ended June 30, 2026 and 2025 was 13.1% and 11.2%, respectively.

In this news release, CNO includes non-GAAP measures to enhance investors’ understanding of management’s view of the business. The non-GAAP measures are not a substitute for GAAP, but rather a supplement to increase transparency by providing a broader perspective. CNO’s definitions of non-GAAP measures may differ from other companies’ definitions. More detailed information including various GAAP and non-GAAP measurements are located at

CNOinc.com in the Investors section under SEC Filings.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS:

This press release may contain forward-looking statements within the meaning of federal securities laws. These prospective statements reflect management’s current expectations, but are not guarantees of future performance. Accordingly, please refer to CNO’s cautionary statement regarding forward-looking statements, and the business environment in which the Company operates, contained in the Company’s Form 10-K for the year ended December 31, 2025 and any subsequent Form 10-Q or Form 10-K on file with the Securities and Exchange Commission and on the Company’s website at

CNOinc.com in the Investors section. CNO specifically disclaims any obligation to update or revise any forward-looking statement because of new information, future developments or otherwise.⁴

EARNINGS RELEASE CONFERENCE CALL WEBCAST:

The Company will host a conference call to discuss results on July 31, 2026 at 11:00 a.m. Eastern Time. During the call, we will be referring to a presentation that will be available at the Investors section of the company's website.

To participate by dial-in, please register at https://events.q4inc.com/attendee/121613442. Upon registering, you will be provided with call details and a registrant ID used to track attendance on the conference call. Reminders will also be sent to registered participants via email.

For those investors who prefer to listen to the call online, we will be broadcasting the call live via webcast. The event can be accessed through the Investors section of the company's website: ir.CNOinc.com. Participants should go to the website at least 15 minutes before the event to register and download any necessary audio software.

ABOUT CNO FINANCIAL GROUP... (truncated)iddle-income America. CNO provides life and health insurance, annuities and financial services through our family of brands, including Bankers Life, Colonial Penn, Optavise and Washington National. Our customers work hard to save for the future, and we help protect their health, income and retirement needs with 3.3 million policies and $39.9 billion in total assets. Our 3,200 associates, 5,100 exclusive agents and more than 6,500 independent partner agents guide individuals, families and businesses through a lifetime of financial decisions. For more information, visit

CNOinc.com.⁵

CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES

## Financial statements

### Income Statement ((Unaudited))

| | 1Q – 2025 | 2Q – 2025 | 3Q – 2025 | 4Q – 2025 | YTD – 2025 | 1Q – 2026 | 2Q – 2026 |
|---|---:|---:|---:|---:|---:|---:|---:|
| Revenues | Insurance policy income | 650.7 | 651.3 | 658.4 | 662.2 | 2,622.6 | 673.4 | 680.7 |
| Net investment income: | General account assets | 375.1 | 378.3 | 382.9 | 406.1 | 1,542.4 | 395 | 411.9 |
| Net investment income: | Policyholder and other special-purpose portfolios | -63.6 | 105.4 | 116.8 | 22.4 | 181 | -64.9 | 185.1 |
| Investment gains (losses): | Realized investment losses | -3.8 | -21.3 | -12.9 | -21.6 | -59.6 | -7.8 | -8.6 |
| Investment gains (losses): | Other investment (losses) gains | -3 | 2.9 | 9.9 | -4.9 | 4.9 | -14.9 | -6.1 |
| Investment gains (losses): | Total investment losses | -6.8 | -18.4 | -3 | -26.5 | -54.7 | -22.7 | -14.7 |
| Investment gains (losses): | Fee revenue and other income | 48.7 | 34.9 | 33.6 | 78.9 | 196.1 | 48.8 | 22.2 |
| Investment gains (losses): | Total revenues | 1,004.1 | 1,151.5 | 1,188.7 | 1,143.1 | 4,487.4 | 1,029.6 | 1,285.2 |
| Benefits and expenses | Insurance policy benefits | 570 | 658.4 | 702.1 | 617.7 | 2,548.2 | 576.6 | 742.5 |
| Benefits and expenses | Liability for future policy benefits remeasurement gain | -12.2 | -12.8 | -30.8 | -14.9 | -70.7 | -6.5 | -15.3 |
| Benefits and expenses | Change in fair value of market risk benefits | 15.3 | -10.9 | -12.4 | -4.4 | -12.4 | 10.7 | -8.3 |
| Benefits and expenses | Interest expense | 62 | 59.1 | 56.6 | 53.2 | 230.9 | 50.9 | 55.3 |
| Benefits and expenses | Amortization of deferred acquisition costs and present value of future profits | 67.4 | 68.6 | 69.9 | 72.1 | 278 | 74.2 | 74.9 |
| Benefits and expenses | Goodwill and other asset impairment |  |  | 96.7 | 5.2 | 101.9 |  |  |
| Benefits and expenses | Gain on extinguishment related to VIEs | -1.5 |  |  |  | -1.5 |  |  |
| Benefits and expenses | Other operating costs and expenses | 275.3 | 271.1 | 270.4 | 302.8 | 1,119.6 | 275.3 | 276.4 |
| Benefits and expenses | Total benefits and expenses | 976.3 | 1,033.5 | 1,152.5 | 1,031.7 | 4,194 | 981.2 | 1,125.5 |
| Benefits and expenses | Income before income taxes | 27.8 | 118 | 36.2 | 111.4 | 293.4 | 48.4 | 159.7 |
| Benefits and expenses | Income tax expense | 6.3 | 26.2 | 13.1 | 18.5 | 64.1 | 10.7 | 33.8 |
| Benefits and expenses | Net income | 21.5 | 91.8 | 23.1 | 92.9 | 229.3 | 37.7 | 125.9 |

### Income Statement ((Unaudited))

| | 1Q – 2025 | 2Q – 2025 | 3Q – 2025 | 4Q – 2025 | YTD – 2025 | 1Q – 2026 | 2Q – 2026 |
|---|---:|---:|---:|---:|---:|---:|---:|
| Insurance product margin (4) | Annuity margin | 54.5 | 54.8 | 72.9 | 56.4 | 238.6 | 58.5 | 60.6 |
| Insurance product margin (4) | Health margin | 126.2 | 134 | 157 | 139.4 | 556.6 | 132.6 | 147.2 |
| Insurance product margin (4) | Life margin | 68.2 | 63.6 | 70.6 | 70 | 272.4 | 65.8 | 71.2 |
| Insurance product margin (4) | Total insurance product margin | 248.9 | 252.4 | 300.5 | 265.8 | 1,067.6 | 256.9 | 279 |
| Insurance product margin (4) | Allocated expenses | -161.2 | -149.4 | -151 | -149.7 | -611.3 | -159.9 | -152.9 |
| Insurance product margin (4) | Income from insurance products (8) | 87.7 | 103 | 149.5 | 116.1 | 456.3 | 97 | 126.1 |
| Insurance product margin (4) | Fee income | -0.8 | 0.8 | -3.9 | 19.1 | 15.2 | 10.6 | -1.2 |
| Insurance product margin (4) | Investment income not allocated to product lines (9) | 38 | 33.8 | 39.5 | 58.1 | 169.4 | 41.7 | 49.4 |
| Insurance product margin (4) | Expenses not allocated to product lines | -20.3 | -25.3 | -22.3 | -19.8 | -87.7 | -19.4 | -23.3 |
| Insurance product margin (4) | Operating earnings before taxes | 104.6 | 112.3 | 162.8 | 173.5 | 553.2 | 129.9 | 151 |
| Insurance product margin (4) | Income tax expense on operating income | -23.5 | -24.8 | -35.6 | -30.1 | -114 | -28.6 | -31.5 |
| Insurance product margin (4) | Net operating income (10) | 81.1 | 87.5 | 127.2 | 143.4 | 439.2 | 101.3 | 119.5 |
| Insurance product margin (4) | Net realized investment losses from disposals, impairments and change in allowance for credit losses | -13.2 | -21.8 | -8.8 | -25.2 | -69 | -15.2 | -13.6 |
| Insurance product margin (4) | Net change in market value of investments recognized in earnings | 6.4 | 3.4 | 5.8 | -1.3 | 14.3 | -7.5 | -1.1 |
| Insurance product margin (4) | Fair value changes related to agent deferred compensation plan |  |  |  | -1.7 | -1.7 |  |  |
| Insurance product margin (4) | Changes in fair value of embedded derivative liabilities and market risk benefits | -69.6 | 25.2 | -18.1 | -1.5 | -64 | -42.4 | 34.6 |
| Insurance product margin (4) | Expenses related to TechMod initiative |  | -3.2 | -7.2 | -9.9 | -20.3 | -13.7 | -9.7 |
| Insurance product margin (4) | Goodwill and other asset impairment |  |  | -96.7 | -5.2 | -101.9 |  |  |
| Insurance product margin (4) | Net loss related to divested business |  |  |  | -17.3 | -17.3 | -1.9 | -1.1 |
| Insurance product margin (4) | Other | -0.4 | 2.1 | -1.6 |  | 0.1 | -0.8 | -0.4 |
| Insurance product margin (4) | Net non-operating income (loss) before taxes | -76.8 | 5.7 | -126.6 | -62.1 | -259.8 | -81.5 | 8.7 |
| Insurance product margin (4) | Income tax (expense) benefit on non-operating income (loss) | 17.2 | -1.4 | 22.5 | 11.6 | 49.9 | 17.9 | -2.3 |
| Insurance product margin (4) | Net non-operating income (loss) | -59.6 | 4.3 | -104.1 | -50.5 | -209.9 | -63.6 | 6.4 |
| Insurance product margin (4) | Net income | 21.5 | 91.8 | 23.1 | 92.9 | 229.3 | 37.7 | 125.9 |
| Per diluted share | Net operating income | 0.79 | 0.87 | 1.29 | 1.47 | 4.4 | 1.05 | 1.26 |
| Per diluted share | Net non-operating income (loss) | -0.58 | 0.04 | -1.05 | -0.52 | -2.1 | -0.66 | 0.07 |
| Per diluted share | Net income | 0.21 | 0.91 | 0.24 | 0.95 | 2.3 | 0.39 | 1.33 |

### Income Statement ((Unaudited))

| | 1Q – 2025 | 2Q – 2025 | 3Q – 2025 | 4Q – 2025 | YTD – 2025 | 1Q – 2026 | 2Q – 2026 |
|---|---:|---:|---:|---:|---:|---:|---:|
| Annuity: | Insurance policy income | 9.8 | 8.4 | 10.7 | 10.4 | 39.3 | 8.7 | 10.2 |
| Annuity: | Net investment income (5) (6) | 148 | 155.3 | 157.7 | 160.3 | 621.3 | 161 | 163.9 |
| Annuity: | Insurance policy benefits | -10.3 | -10 | 6.2 | -10.9 | -25 | -11.6 | -9 |
| Annuity: | Interest credited (6) | -68.3 | -73.4 | -75.4 | -76.4 | -293.5 | -71.8 | -75.7 |

### Income Statement ((Unaudited))

| | 1Q – 2025 | 2Q – 2025 | 3Q – 2025 (a) | 4Q – 2025 | YTD – 2025 | 1Q – 2026 | 2Q – 2026 (b) |
|---|---:|---:|---:|---:|---:|---:|---:|
| Net gain from operations before interest expense and federal income taxes | 29 | 37.7 | 45.2 | 95.3 | 207.2 | 37.4 | 62.9 |
| Interest expense on surplus debentures held by parent company | 15.5 | 15.7 | 29.4 | 15.3 | 75.9 | 14.4 | 14.5 |
| Net gain from operations before federal income taxes | 13.5 | 22 | 15.8 | 80 | 131.3 | 23 | 48.4 |
| Federal income tax expense (benefit) |  |  | 20.9 | 61.6 | 82.5 |  | 13 |
| Net gain (loss) from operations before net realized capital gains (losses) | 13.5 | 22 | -5.1 | 18.4 | 48.8 | 23 | 35.4 |
| Net realized capital losses | -1.2 | -2.6 | -11.1 | -48.5 | -63.4 | -1.5 | -16.4 |
| Net income (loss) | 12.3 | 19.4 | -16.2 | -30.1 | -14.6 | 21.5 | 19 |
| Capital and surplus | 1,422.3 | 1,417.8 | 1,403.1 | 1,405.3 | 1,405.3 | 1,399.1 | 1,413.6 |
| Asset valuation reserve (AVR) | 428.5 | 459.3 | 485 | 508.7 | 508.7 | 534.2 | 566.1 |
| Capital, surplus and AVR | 1,850.8 | 1,877.1 | 1,888.1 | 1,914 | 1,914 | 1,933.3 | 1,979.7 |
| Interest maintenance reserve (IMR) | 331.5 | 315.8 | 298.3 | 252.6 | 252.6 | 246.2 | 243.6 |
| Total statutory capital, surplus, AVR & IMR | 2,182.3 | 2,192.9 | 2,186.4 | 2,166.6 | 2,166.6 | 2,179.5 | 2,223.3 |

### Income Statement ((Unaudited))

| | 1Q – 2025 | 2Q – 2025 | 3Q – 2025 | 4Q – 2025 | YTD – 2025 | 1Q – 2026 | 2Q – 2026 |
|---|---:|---:|---:|---:|---:|---:|---:|
| Excluding variable components: | From general account assets | 28 | 24.1 | 20.6 | 32.3 | 105 | 23.4 | 23.5 |
| Excluding variable components: | Other investment income | 10.9 | 6.6 | 1.8 | 3.2 | 22.5 | 3.2 | 3 |
| Federal Home Loan Bank ("FHLB") program: | Investment income | 35.4 | 36.6 | 40.6 | 37.8 | 150.4 | 36.9 | 42.6 |
| Federal Home Loan Bank ("FHLB") program: | Interest expense (a) | -26 | -27.7 | -29.7 | -27.8 | -111.2 | -25.9 | -30.3 |
| Federal Home Loan Bank ("FHLB") program: | Net spread income on FHLB program | 9.4 | 8.9 | 10.9 | 10 | 39.2 | 11 | 12.3 |
| Funding agreement-backed notes ("FABN") program: | Investment income | 34.3 | 36.9 | 37.6 | 42.9 | 151.7 | 46.5 | 49.3 |
| Funding agreement-backed notes ("FABN") program: | Expenses (a)(b) | -27.9 | -27.7 | -29.1 | -32.9 | -117.6 | -36.7 | -37.5 |
| Funding agreement-backed notes ("FABN") program: | Net spread income on FABN program | 6.4 | 9.2 | 8.5 | 10 | 34.1 | 9.8 | 11.8 |
| Funding agreement-backed notes ("FABN") program: | Interest expense on corporate debt (a) | -27.2 | -24.6 | -20.3 | -20.4 | -92.5 | -20.3 | -20.4 |
| Funding agreement-backed notes ("FABN") program: | Interest expense on financing arrangements (a) | -1 | -1 | -0.8 | -0.9 | -3.7 | -0.7 | -0.7 |
| Funding agreement-backed notes ("FABN") program: | Total excluding variable components | 26.5 | 23.2 | 20.7 | 34.2 | 104.6 | 26.4 | 29.5 |
| Net income from assets supporting deferred compensation plans: | Investment income | -2.1 | 15 | 11.3 | 4.6 | 28.8 | -5.9 | 17.5 |
| Net income from assets supporting deferred compensation plans: | Expenses (a) | 2.8 | -14.9 | -10.4 | -4.2 | -26.7 | 4 | -19.9 |
| Net income from assets supporting deferred compensation plans: | Net income from assets supporting deferred compensation plans | 0.7 | 0.1 | 0.9 | 0.4 | 2.1 | -1.9 | -2.4 |
| Alternative investment income (loss): | Total alternative income | 12.9 | 11.7 | 15.8 | 24.1 | 64.5 | 17.7 | 21.2 |
| Alternative investment income (loss): | Allocated to product lines | -6 | -6 | -5.9 | -5 | -22.9 | -5.2 | -6.1 |
| Alternative investment income (loss): | Allocated to FABN program |  | -0.7 | 0.1 | -0.1 | -0.7 | -0.8 | -1.1 |
| Alternative investment income (loss): | Excess alternative investment income (loss) | 6.9 | 5 | 10 | 19 | 40.9 | 11.7 | 14 |

### Income Statement (Three months ended)

| | Three months ended – September 30, 2025 – Actual results | Three months ended – September 30, 2025 – Significant items | Three months ended – September 30, 2025 – Excluding significant items |
|---|---:|---:|---:|
| Insurance product margin (4) | Annuity margin | 72.9 | -16.6 | 56.3 |
| Insurance product margin (4) | Health margin | 157 | -21.1 | 135.9 |
| Insurance product margin (4) | Life margin | 70.6 | -3.6 | 67 |
| Insurance product margin (4) | Total insurance product margin | 300.5 | -41.3 | 259.2 |
| Insurance product margin (4) | Allocated expenses | -151 |  | -151 |
| Insurance product margin (4) | Income from insurance products (5) | 149.5 | -41.3 | 108.2 |
| Insurance product margin (4) | Fee income | -3.9 |  | -3.9 |
| Insurance product margin (4) | Investment income not allocated to product lines (9) | 39.5 |  | 39.5 |
| Insurance product margin (4) | Expenses not allocated to product lines | -22.3 |  | -22.3 |
| Insurance product margin (4) | Operating earnings before taxes | 162.8 | -41.3 | 121.5 |
| Insurance product margin (4) | Income tax (expense) benefit on operating income | -35.6 | 9.1 | -26.5 |
| Insurance product margin (4) | Net operating income (10) | 127.2 | -32.2 | 95 |
| Insurance product margin (4) | Net operating income per diluted share | 1.29 | -0.33 | 0.96 |

### Income Statement (Three months ended)

| | Three months ended – March 31, 2025 – Actual results | Three months ended – March 31, 2025 – Significant items | Three months ended – March 31, 2025 – Excluding significant items |
|---|---:|---:|---:|
| Insurance product margin (4) | Annuity margin | 54.5 |  | 54.5 |
| Insurance product margin (4) | Health margin | 126.2 |  | 126.2 |
| Insurance product margin (4) | Life margin | 68.2 | -6.8 | 61.4 |
| Insurance product margin (4) | Total insurance product margin | 248.9 | -6.8 | 242.1 |
| Insurance product margin (4) | Allocated expenses | -161.2 |  | -161.2 |
| Insurance product margin (4) | Income from insurance products (5) | 87.7 | -6.8 | 80.9 |
| Insurance product margin (4) | Fee income | -0.8 |  | -0.8 |
| Insurance product margin (4) | Investment income not allocated to product lines (9) | 38 |  | 38 |
| Insurance product margin (4) | Expenses not allocated to product lines | -20.3 |  | -20.3 |
| Insurance product margin (4) | Operating earnings before taxes | 104.6 | -6.8 | 97.8 |
| Insurance product margin (4) | Income tax (expense) benefit on operating income | -23.5 | 1.5 | -22 |
| Insurance product margin (4) | Net operating income (10) | 81.1 | -5.3 | 75.8 |
| Insurance product margin (4) | Net operating income per diluted share | 0.79 | -0.05 | 0.74 |

### Income Statement (were unaffected by significant items. Significant items are detailed in note (6).)

| | Per diluted share – Quarter ended – June 30, – 2026 | Per diluted share – Quarter ended – June 30, – 2025 | Per diluted share – Quarter ended – June 30, – % change | Quarter ended – June 30, – 2026 | Quarter ended – June 30, – 2025 | Quarter ended – June 30, – % change |
|---|---:|---:|---:|---:|---:|---:|
| Income from insurance products (b) | 1.33 | 1.03 | 29.0% | 126.1 | 103 | 22.0% |
| Fee income | -0.01 | 0.01 | n/m | -1.2 | 0.8 | n/m |
| Investment income not allocated to product lines (c) | 0.52 | 0.33 | 58.0% | 49.4 | 33.8 | 46.0% |
| Expenses not allocated to product lines | -0.25 | -0.25 |  | -23.3 | -25.3 | -8.0% |
| Operating earnings before taxes | 1.59 | 1.12 |  | 151 | 112.3 |  |
| Income tax expense on operating income | -0.33 | -0.25 | 32.0% | -31.5 | -24.8 | 27.0% |
| Net operating income (1) | 1.26 | 0.87 | 45.0% | 119.5 | 87.5 | 37.0% |
| Net realized investment losses from disposals, impairments and change in allowance for credit losses | -0.14 | -0.22 |  | -13.6 | -21.8 |  |
| Net change in market value of investments recognized in earnings | -0.01 | 0.03 |  | -1.1 | 3.4 |  |
| Changes in fair value of embedded derivative liabilities and market risk benefits | 0.36 | 0.25 |  | 34.6 | 25.2 |  |
| Expenses related to TechMod initiative | -0.1 | -0.03 |  | -9.7 | -3.2 |  |
| Net loss related to divested business | -0.01 |  |  | -1.1 |  |  |
| Other | -0.01 | 0.02 |  | -0.4 | 2.1 |  |
| Non-operating income before taxes | 0.09 | 0.05 |  | 8.7 | 5.7 |  |
| Income tax expense on non-operating income | -0.02 | -0.01 |  | -2.3 | -1.4 |  |

### Income Statement (Quarter ended — ___________________________________________________________________________________________________)

| | Quarter ended – June 30, – 2026 | Quarter ended – June 30, – 2025 |
|---|---:|---:|
| Net Income | 279.6 | 305.5 |
| Net operating income (a non-GAAP financial measure) | 491.4 | 425.8 |
| Net operating income, excluding significant items | 459.2 | 401.7 |
| Average of each of the trailing four quarters average: | Shareholders’ equity | 2,576.2 | 2,558.5 |
| Average of each of the trailing four quarters average: | Accumulated other comprehensive loss | 1,167.3 | 1,271.2 |
| Average of each of the trailing four quarters average: | Shareholders’ equity, excluding accumulated other comprehensive loss | 3,743.5 | 3,829.7 |
| Average of each of the trailing four quarters average: | Net operating loss carryforwards | -248.1 | -232.4 |
| Average of each of the trailing four quarters average: | Shareholders' equity, excluding accumulated other comprehensive loss and net operating loss carryforwards | 3,495.4 | 3,597.3 |
| Ratios: | Return on equity | 10.9 | 11.9 |
| Ratios: | Operating return on equity (a non-GAAP financial measure) (5) | 14.1 | 11.8 |
| Ratios: | Operating return on equity, excluding significant items (a non-GAAP financial measure) (5) | 13.1 | 11.2 |

### Income Statement (Three months ended — (unaudited))

| | Three months ended – June 30, – 2026 | Three months ended – June 30, – 2025 | Six months ended – June 30, – 2026 | Six months ended – June 30, – 2025 |
|---|---:|---:|---:|---:|
| Revenues: | Insurance policy income | 680.7 | 651.3 | 1,354.1 | 1,302 |
| Net investment income: | General account assets | 411.9 | 378.3 | 806.9 | 753.4 |
| Net investment income: | Policyholder and other special-purpose portfolios | 185.1 | 105.4 | 120.2 | 41.8 |
| Investment gains (losses): | Realized investment losses | -8.6 | -21.3 | -16.4 | -25.1 |
| Investment gains (losses): | Other investment (losses) gains | -6.1 | 2.9 | -21 | -0.1 |
| Investment gains (losses): | Total investment losses | -14.7 | -18.4 | -37.4 | -25.2 |
| Investment gains (losses): | Fee revenue and other income | 22.2 | 34.9 | 71 | 83.6 |
| Investment gains (losses): | Total revenues | 1,285.2 | 1,151.5 | 2,314.8 | 2,155.6 |
| Benefits and expenses: | Insurance policy benefits | 742.5 | 658.4 | 1,319.1 | 1,228.4 |
| Benefits and expenses: | Liability for future policy benefits remeasurement gain | -15.3 | -12.8 | -21.8 | -25 |
| Benefits and expenses: | Change in fair value of market risk benefits | -8.3 | -10.9 | 2.4 | 4.4 |
| Benefits and expenses: | Interest expense | 55.3 | 59.1 | 106.2 | 121.1 |
| Benefits and expenses: | Amortization of deferred acquisition costs and present value of future profits | 74.9 | 68.6 | 149.1 | 136 |
| Benefits and expenses: | Gain on extinguishment of borrowings related to variable interest entities |  |  |  | -1.5 |
| Benefits and expenses: | Other operating costs and expenses | 276.4 | 271.1 | 551.7 | 546.4 |
| Benefits and expenses: | Total benefits and expenses | 1,125.5 | 1,033.5 | 2,106.7 | 2,009.8 |
| Benefits and expenses: | Income before income taxes | 159.7 | 118 | 208.1 | 145.8 |
| Benefits and expenses: | Income tax expense | 33.8 | 26.2 | 44.5 | 32.5 |
| Benefits and expenses: | Net income | 125.9 | 91.8 | 163.6 | 113.3 |
| Basic: | Weighted average shares outstanding | 93,194,000 | 98,572,000 | 93,636,000 | 99,658,000 |
| Basic: | Net income | 1.35 | 0.93 | 1.75 | 1.14 |
| Diluted: | Weighted average shares outstanding | 94,952,000 | 100,386,000 | 95,545,000 | 101,728,000 |
| Diluted: | Net income | 1.33 | 0.91 | 1.71 | 1.11 |

### Income Statement (in millions)

| | Net operating – income | Significant – items | Net operating – income, – excluding – significant – items (a) | Net operating – income, – excluding – significant – items - trailing – four quarters | Net – income (loss) | Net – income - – trailing – four quarters |
|---|---:|---:|---:|---:|---:|---:|
| 3Q24 | 119.2 | -21.9 | 97.3 | 376.9 | 9.3 | 274.2 |
| 4Q24 | 138 | 3.1 | 141.1 | 410.5 | 182.9 | 420.8 |
| 1Q25 | 81.1 | -5.3 | 75.8 | 428.8 | 21.5 | 330 |
| 2Q25 | 87.5 |  | 87.5 | 401.7 | 91.8 | 305.5 |
| 3Q25 | 127.2 | -32.2 | 95 | 399.4 | 23.1 | 319.3 |
| 4Q25 | 143.4 |  | 143.4 | 401.7 | 92.9 | 229.3 |
| 1Q26 | 101.3 |  | 101.3 | 427.2 | 37.7 | 245.5 |
| 2Q26 | 119.5 |  | 119.5 | 459.2 | 125.9 | 279.6 |

### Income Statement (Trailing four quarters — A reconciliation of pre-tax operating earnings (a non-GAAP financial measure) to net income is as follows (dollars in millions):)

| | Trailing four quarters – 2Q26 | Trailing four quarters – 2Q25 |
|---|---:|---:|
| Pre-tax operating earnings (a non-GAAP financial measure) | 617.2 | 544.3 |
| Income tax expense | -125.8 | -118.5 |
| Net operating income | 491.4 | 425.8 |
| Non-operating items: | Net realized investment losses from disposals, impairments and change in allowance for credit losses | -62.8 | -81.2 |
| Non-operating items: | Net change in market value of investments recognized in earnings | -4.1 | 15.5 |
| Non-operating items: | Changes in fair value of embedded derivative liabilities and market risk benefits | -27.4 | -78.9 |
| Non-operating items: | Fair value changes related to the agent deferred compensation plan | -1.7 | 3.1 |
| Non-operating items: | Expenses related to TechMod initiative | -40.5 | -3.2 |
| Non-operating items: | Goodwill and other asset impairment | -101.9 |  |
| Non-operating items: | Net loss related to divested business | -20.3 |  |
| Non-operating items: | Other | -2.8 | -10.7 |
| Non-operating items: | Non-operating loss before taxes | -261.5 | -155.4 |
| Non-operating items: | Income tax benefit on non-operating loss | 49.7 | 35.1 |
| Non-operating items: | Net non-operating loss | -211.8 | -120.3 |
| Non-operating items: | Net income | 279.6 | 305.5 |

### Income Statement (in millions)

| | 1Q24 |  | 1Q24 |  | 2Q24 |  | 2Q24 |  | 3Q24 |  | 3Q24 |  | 4Q24 |  | 4Q24 |  |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| (a non-GAAP financial measure) |  |  | 3,536.8 |  |  |  | 3,596.7 |  |  |  | 3,529.9 |  |  |  | 3,810 |  |

### Income Statement (Trailing four quarter average (in millions))

| | Trailing four quarter average – 2Q26 | Trailing four quarter average – 2Q25 |
|---|---:|---:|
| Consolidated capital, excluding accumulated other comprehensive |  | 3,495.4 | 3,597.3 |
| Consolidated capital, excluding accumulated other comprehensive | Net operating loss carryforwards | 248.1 | 232.4 |
| Consolidated capital, excluding accumulated other comprehensive | Accumulated other comprehensive loss | -1,167.3 | -1,271.2 |
| Consolidated capital, excluding accumulated other comprehensive | Common shareholders' equity | 2,576.2 | 2,558.5 |

### Income Statement (Three months ended (dollars in millions, except per share data))

| | Three months ended – September 30, 2025 – Actual results | Three months ended – September 30, 2025 – Significant items | Three months ended – September 30, 2025 – Excluding significant items |
|---|---:|---:|---:|
| Insurance product margin | Annuity margin | 72.9 | -16.6 | 56.3 |
| Insurance product margin | Health margin | 157 | -21.1 | 135.9 |
| Insurance product margin | Life margin | 70.6 | -3.6 | 67 |
| Insurance product margin | Total insurance product margin | 300.5 | -41.3 | 259.2 |
| Insurance product margin | Allocated expenses | -151 |  | -151 |
| Insurance product margin | Income from insurance products | 149.5 | -41.3 | 108.2 |
| Insurance product margin | Fee income | -3.9 |  | -3.9 |
| Insurance product margin | Investment income not allocated to product lines | 39.5 |  | 39.5 |
| Insurance product margin | Expenses not allocated to product lines | -22.3 |  | -22.3 |
| Insurance product margin | Operating earnings before taxes | 162.8 | -41.3 | 121.5 |
| Insurance product margin | Income tax (expense) benefit on operating income | -35.6 | 9.1 | -26.5 |
| Insurance product margin | Net operating income | 127.2 | -32.2 | 95 |
| Insurance product margin | Net operating income per diluted share | 1.29 | -0.33 | 0.96 |

### Income Statement (Three months ended — Comprised of $41.3 million of the net favorable impact arising from our comprehensive annual actuarial review.)

| | Three months ended – March 31, 2025 – Actual results | Three months ended – March 31, 2025 – Significant items | Three months ended – March 31, 2025 – Excluding significant items |
|---|---:|---:|---:|
| Insurance product margin | Annuity margin | 54.5 |  | 54.5 |
| Insurance product margin | Health margin | 126.2 |  | 126.2 |
| Insurance product margin | Life margin | 68.2 | -6.8 | 61.4 |
| Insurance product margin | Total insurance product margin | 248.9 | -6.8 | 242.1 |
| Insurance product margin | Allocated expenses | -161.2 |  | -161.2 |
| Insurance product margin | Income from insurance products | 87.7 | -6.8 | 80.9 |
| Insurance product margin | Fee income | -0.8 |  | -0.8 |
| Insurance product margin | Investment income not allocated to product lines | 38 |  | 38 |
| Insurance product margin | Expenses not allocated to product lines | -20.3 |  | -20.3 |
| Insurance product margin | Operating earnings before taxes | 104.6 | -6.8 | 97.8 |
| Insurance product margin | Income tax (expense) benefit on operating income | -23.5 | 1.5 | -22 |
| Insurance product margin | Net operating income | 81.1 | -5.3 | 75.8 |
| Insurance product margin | Net operating income per diluted share | 0.79 | -0.05 | 0.74 |

### Balance Sheet ((Unaudited))

| | Mar-25 | Jun-25 | Sep-25 | Dec-25 | Mar-26 | Jun-26 |
|---|---:|---:|---:|---:|---:|---:|
| Investments: | Fixed maturities, available for sale, at fair value | 23,283 | 23,047 | 23,405.3 | 23,886.8 | 23,881.1 | 24,495.7 |
| Investments: | Equity securities at fair value | 349.1 | 387.4 | 377.2 | 389.2 | 332.8 | 337.2 |
| Investments: | Mortgage loans | 2,601.2 | 2,834.3 | 3,042.7 | 3,256.8 | 3,347.8 | 3,356.3 |
| Investments: | Policy loans | 136.4 | 137.6 | 141.2 | 140.9 | 141.8 | 144.2 |
| Investments: | Trading securities | 308 | 308.3 | 296.9 | 294.8 | 280.2 | 258.6 |
| Investments: | Investments held by variable interest entities | 380.2 | 376.9 | 296.8 | 293 | 287.4 | 292.3 |
| Investments: | Other invested assets | 1,386.7 | 1,500.5 | 1,617 | 1,737 | 1,695.1 | 1,858.6 |
| Investments: | Total investments | 28,444.6 | 28,592 | 29,177.1 | 29,998.5 | 29,966.2 | 30,742.9 |
| Investments: | Cash and cash equivalents - unrestricted | 928.2 | 766 | 1,218.3 | 956.1 | 1,129.5 | 1,289.7 |
| Investments: | Cash and cash equivalents held by variable interest entities | 96.6 | 50 | 23.3 | 27.4 | 24.8 | 16.3 |
| Investments: | Accrued investment income | 289.6 | 279.4 | 282 | 286 | 284.2 | 302.5 |
